Trial Profile
A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release Vs Buprenorphine Transdermal System (BTDS) 5 in Subjects With Moderate to Severe Low Back Pain: A 52-Week Open-label Extension Phase of BUP3015.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2017
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary) ; Oxycodone
- Indications Back pain
- Focus Adverse reactions; Therapeutic Use
- 24 Sep 2011 Results published in the Journal of Pain, according to a Purdue Pharma media release.
- 21 May 2010 New trial record
- 21 May 2010 New trial record